Clinical Trials
1400
85 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1836
Unknown
6
0.4%
Completed
855
61.1%
Enrolling By Invitation
7
0.5%
Not yet recruiting
25
1.8%
No Longer Available
2
0.1%
Terminated
174
12.4%
Recruiting
197
14.1%
Suspended
7
0.5%
Withdrawn
74
5.3%
Active, not recruiting
53
3.8%
No approval data available
- The NIH has awarded a first installment of $4.6 million, part of up to $12.8 million over three years, to a multi-university team modeling drug-hormone interactions in women. - Thirteen researchers from Michigan State, Rutgers, Emory, Tulane, and other institutions will build computational models integrating age and reproductive cycle stage into drug predictions. - The project targets metabolic drugs such as metformin, insulin, and GLP-1 agents, whose effects may vary with shifting female hormone levels. - All computer models and data will be freely available worldwide, with findings intended to inform NIH guidelines and national safety standards.
- Korean researchers used an oxygen-to-nitrogen atom swap to convert the furan group in natural products into pyrroles, dramatically altering biological activity. - The 15N-labeled limonin analog 15N-LIMO bound metabolic and mitochondrial proteins such as NNT instead of the kinases targeted by parent limonin. - Both limonin and 15N-LIMO showed antifibrotic activity through different mechanisms, with 15N-LIMO acting on mitochondrial redox systems and proving less cytotoxic. - A separate Ritsumeikan team reported a chlorine-guided, room-temperature method that deletes a carbonyl group from hydroxycoumarins to form coumaranones in over 99% yield.
- COVID-19 cases are rising again across the United States, with the virus spreading most in the South and West while also increasing in the Northeast and Midwest. - Experts describe this summer's wave as milder than previous years, with growing immunity from prior infections and vaccinations reducing disease severity. - Older adults, infants, and immunocompromised people remain most vulnerable to severe COVID-19, according to epidemiologist Caitlin Rivers of Johns Hopkins University. - Updated vaccines targeting the dominant circulating strain are expected soon, and a new post-exposure drug called Xocova may help reduce the chance of developing illness.
- An oral live-attenuated Shigella sonnei vaccine candidate, WRSs2, achieved 89% protection against shigellosis in a phase 2 controlled human infection trial published in The Lancet Infectious Diseases. - Only 3 of 34 vaccinated participants developed shigellosis compared with 21 of 26 placebo recipients, with just 3% experiencing severe symptoms versus 69% in the placebo group. - The trial enrolled 108 healthy adults aged 18–49, and no vaccine-related serious adverse events were reported, supporting a favorable safety profile. - Researchers emphasize further optimization is needed, including studies in children in endemic regions, as Shigella causes hundreds of thousands of deaths annually worldwide with no licensed vaccine currently available.
- Moonlight Therapeutics has initiated SURVEYOR, a Phase I clinical trial evaluating MOON101, an investigational microneedle-delivered immunotherapy for peanut allergy treatment. - The first-in-human study will enroll approximately 40 participants aged 4-55 years across multiple U.S. sites to assess safety and tolerability of the intradermal therapy. - MOON101 utilizes a minimally invasive skin stamp containing microneedles that deliver microgram doses of peanut extract, designed for potential at-home administration. - The trial follows FDA review of the company's IND application and is supported by a multi-million-dollar NIAID Fast-Track grant.
- Secretary of State Marco Rubio announced that Americans testing positive for Ebola at a new U.S. quarantine facility in Kenya could be sent to the U.S. for treatment, marking a shift from prior administration statements. - The 50-bed facility at Laikipia Air Base in Kenya is designed primarily for asymptomatic Americans exposed to Ebola, with symptomatic individuals to be evacuated to Europe or the U.S. for advanced care. - NIH Director Dr. Jay Bhattacharya emphasized the goal is preventing "inadvertent entry" of Ebola into the U.S., with over 2,000 passengers already screened at U.S. airports. - The outbreak, caused by the Bundibugyo strain, may have begun as early as February 2022, with over 230 deaths reported in the Democratic Republic of Congo.
- Racura Oncology has received governance approval from Monash Health for its HARNESS-1 Phase 1a/b trial testing RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. - The trial will enroll 12-40 patients using ctDNA screening and Bayesian dose escalation to determine maximum tolerated dose, with site initiation training scheduled for March 23, 2026. - RC220 is an RNA/DNA G4 binder designed to enhance efficacy and safety in combination therapy, addressing resistance to osimertinib in lung cancer patients. - The company maintains $20.94 million in cash through December 2025, providing funding runway through 2027 to support clinical development programs.
- A French phase III trial (UNICANCER HypoG-01) demonstrated that 3-week hypofractionated radiotherapy was noninferior to standard 5-week treatment in preventing lymphedema in early breast cancer patients. - The study of 1,221 women showed comparable lymphedema rates between 3-week (23.4%) and 5-week (22.2%) radiotherapy regimens with similar safety profiles. - Ultra-hypofractionated radiotherapy using just 5 fractions proved feasible in locally advanced breast cancer, with 46.6% of patients showing favorable clinical response rates. - These findings support shorter radiation treatment courses that could improve patient convenience while maintaining therapeutic efficacy and safety.
- Iterion Therapeutics has dosed the first patient in a clinical study evaluating tegavivint, a first-in-class Wnt/β-catenin pathway inhibitor, combined with gemcitabine for relapsed or refractory osteosarcoma. - Tegavivint is a small-molecule inhibitor of TBL1 that has already demonstrated favorable tolerability and encouraging monotherapy clinical responses in hepatocellular carcinoma and desmoid tumors. - The trial targets osteosarcoma, the most common malignant bone tumor in children and adolescents, where Wnt/β-catenin signaling is highly active in relapsed and metastatic disease. - The drug has received both Orphan Drug Designation and Pediatric Rare Disease Designation from the FDA for osteosarcoma treatment.
- Thiogenesis Therapeutics announced a new investigator-initiated study collaboration with Dr. Larry Greenbaum at Emory University to evaluate TTI-0102, a next-generation cysteamine-based prodrug for nephropathic cystinosis. - TTI-0102 demonstrates sustained 24-hour cysteamine exposure with potential once-daily dosing and achieves target exposure at approximately half the daily dose of existing therapies. - The company is preparing for Phase 3 development using a non-inferiority design against standard-of-care cysteamine therapy under FDA's 505(b)(2) regulatory pathway. - Nephropathic cystinosis affects an estimated 2,000-2,500 patients worldwide, representing a global market opportunity of over $300 million.
